Lilly’s oral obesity drug momentum and Google’s AI rollout set the tone for late-session trading
Fresh company data on Eli Lilly’s oral obesity candidate and a new wave of Google AI features steered attention in the final hour of trading, with investors weighing implications for growth, margins, and market leadership across healthcare and tech.